PCMC
GERM

Planning Capital Management Corporation’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Planning Capital Management Corporation’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$19 – 925
2024
Q2 		$19 Buy
+1
New +$18 ﹤0.01% 709

Other funds holding GERM

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Planning Capital Management Corporation's GERM Position: Q3 2024 in Review

Planning Capital Management Corporation sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2024, closing a stake of 1 share — an estimated $19 sold.

Planning Capital Management Corporation first reported a position in GERM in Q2 2024 and held it in 1 quarter. The position peaked at $19 in Q2 2024. 1 fund tracked by Wall St. Rank holds GERM as of Q3 2024.

  • Planning Capital Management Corporation reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2024 after selling out during the quarter.
  • Planning Capital Management Corporation sold 1 Amplify Treatments, Testing and Advancements ETF share in Q3 2024, an estimated $19.
  • Planning Capital Management Corporation first reported a position in Amplify Treatments, Testing and Advancements ETF in Q2 2024 and held it in 1 quarter.
  • Planning Capital Management Corporation's Amplify Treatments, Testing and Advancements ETF position peaked at $19 in Q2 2024.
  • 1 fund tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.